Eli Lilly investing $4.5 billion more into LEAP district
Eli Lilly investing $4.5 billion more into the LEAP district; residents question IEDC's transparency
The company’s first two investments in the district were for a manufacturing site. The new site will focus on research, but some residents feel the IEDC has not been transparent about the project.
Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized ...
Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer's disease, ALS and other brain ...
As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of ...
The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...
Lilly will add the center to a site in Lebanon, Indiana, where it is already spending about $9 billion to improve ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.
The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are ...
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...
AstraZeneca has paid CSPC Pharmaceutical Group $100 million for a preclinical cardiovascular disease drug candidate. The deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback